07:00 , Oct 8, 2015 |  BC Innovations  |  Product R&D

Medicines Co.'s double play

While inhibiting β-lactamases is one of the dominant strategies for combating antibiotic resistance, companies have only had success targeting one of the two classes of the enzyme, serine β-lactamases, and have made little progress against...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Company News

GlaxoSmithKline pharmaceuticals news

GlaxoSmithKline said it will invest about £200 million ($327.4 million) for manufacturing in the U.K. The pharma said it will build new manufacturing facilities at its Ware site and a new bulk sterile building and...
03:11 , Dec 12, 2013 |  BC Extra  |  Company News

GSK investing additional L200M in U.K. manufacturing

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will invest about L200 million ($327.4 million) for manufacturing in the U.K. The pharma said it will build new manufacturing facilities at its Ware site as well as a...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

American Society of Clinical Oncology (ASCO) regulatory update

ASCO issued a clinical practice guideline to manage neutropenia with fever and prevent related infections in patients with cancer. The guideline for adult patients specifically recommends preventive treatment with antibacterial and antifungal drugs - preferably...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Dr. Reddy's, GlaxoSmithKline deal

Dr. Reddy completed its previously announced acquisition of GlaxoSmithKline's penicillin manufacturing site in Bristol, Tenn., and U.S. rights to Augmentin amoxicillin/clavulanate and Amoxil amoxicillin. Further terms were not disclosed (see BioCentury, Dec. 6, 2010). Dr....
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

Dr. Reddy's, GlaxoSmithKline deal

GlaxoSmithKline will transfer ownership of its penicillin manufacturing site in Bristol, Tenn., and U.S. rights to Augmentin amoxicillin/clavulanate and Amoxil amoxicillin to Dr. Reddy's. GSK will retain ex-U.S. rights for the products. The deal is...
08:00 , Jan 11, 2010 |  BC Week In Review  |  Clinical News

Amoxicillin clavulanate regulatory update

Ranbaxy's Ohm Laboratories Inc. unit received a warning letter from FDA citing certain current good manufacturing practices (cGMP) violations at the company's liquid manufacturing facility in Gloversville, N.Y. The letter was issued based on results...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis (TB) β-lactamase (BLAC) In vitro studies suggest that a combination of meropenem and clavulanate could help treat drug-resistant strains...
07:00 , Mar 12, 2009 |  BC Innovations  |  Targets & Mechanisms

Ganging up on TB

Work by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that two FDA-approved antibiotics-meropenem and clavulanate-could be used in combination to overcome drug-resistant Mycobacterium tuberculosis . 1 Although the fact that meropenem...
08:00 , Dec 17, 2007 |  BioCentury  |  Finance

Ebb & Flow

Dashing the hopes of buysiders,...